An Assessment of Serum Selenium Concentration in Women with Ovarian Cancer

• Published in: Nutrients Vol. 15; no. 4; p. 850
• Main Authors: Kluza, Marek, Paszek, Sylwia, Kluza, Katarzyna, Januszek, Sławomir, Potocka, Natalia, Skrzypa, Marzena, Zuchowska, Alina, Wróbel, Andrzej, Baszuk, Piotr, Marciniak, Wojciech, Misiek, Marcin, Lubiński, Jan, Gronwald, Jacek, Zawlik, Izabela, Kluz, Tomasz
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-02-2023; MDPI
• Subjects: Birth control; Calibration; DNA methylation; Female; Gynecology; Humans; Malignancy; Medical prognosis; micronutrients; Ovarian cancer; Ovarian Neoplasms; Prospective Studies; Questionnaires; Reagents; Selenium; serum selenium level; Statistical analysis; Ultrasonic imaging; Womens health; Poland; United States > US; serum selenium level; micronutrients; selenium; ovarian cancer
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu15040850

Available studies on the effect of serum selenium levels on the risk of malignancies show some conflicting results. In this study, we investigated the correlation between serum selenium levels and ovarian cancer occurrence.
314 women (157 diseased patients and 157 healthy ones) matched in terms of age and BMI were included in the study. The measurements of selenium in the collected blood samples were performed using an ICP mass spectrometer. Univariable and multivariable analyzes were performed to determine the relationship between the factors under the study and the occurrence of ovarian cancer.
The mean concentration of selenium was lower among diseased ones than among controls (53.31 μg/L vs. 78.99 μg/L). A decrease in selenium concentration was noticed with the advancement of ovarian cancer. In univariable and multivariable analyzes, a clear relationship between low selenium concentration and the occurrence of ovarian cancer was found (35.3 (95% CI: 11.2-111;
< 0.001) and 45.8 (95% CI: 12.8-164;
< 0.001)).
The studied patients with ovarian cancer are characterized by statistically significant lower serum selenium levels than patients from the control group. Among the study group, a decrease in selenium concentration was observed with an increase in the FIGO stage. The determination of the role of selenium as a prophylactic factor in ovarian cancer requires further prospective studies.